# US 2001/0036948 A1 · Inhibiting proliferation of arterial smooth muscle cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0036948 A1
- Document ID: US20010036948A1
- Status: Published application
- Kind: A1
- Application number: 09/878,831
- Filed: 2001-06-11
- Published: 2001-11-01
- Earliest claimed: 1998-06-11
- Inventors: John E. Hearst; William M. Greenman; Susan Wollowitz; Ryan D. Alfonso
- Web page: https://patentgrep.com/patent/US20010036948A1

## CPC

- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6957: {the form being a device or a kit, e.g. stents or microdevices}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compositions for inhibiting the proliferation of smooth muscle cells at a site of vascular injury. The methods include intravascular administration of a reactive compound to the site of injury, without the requirement for activation or sustained release of the compound.

## Claims

### Claim 1

A method for inhibiting restenosis, the method comprising local administration of an alkylating compound to a site of vascular recanalization, wherein said alkylating compound comprises a nucleic acid binding ligand.

### Claim 2 (depends on 1)

The method of claim 1, wherein the alkylating compound comprises a chemical group which forms a covalent bond with a nucleic acid.

### Claim 3 (depends on 2)

The method of claim 2, wherein the chemical group is selected from the group consisting of mustards, mustard intermediates and mustard equivalents.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mustard is an aliphatic mustard.

### Claim 5 (depends on 2)

The method of claim 2, wherein the nucleic acid binding ligand is selected from the group consisting of intercalators, minor groove binders, major groove binders, electrostatic binders, nucleic acids, and derivatives thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the intercalator is an acridine or acridine derivative.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound is a quinacrine mustard.

### Claim 8 (depends on 2)

The method of claim 2, wherein the nucleic acid binding ligand is covalently bonded to a frangible linker, wherein the frangible linker is covalently bonded to the chemical group.

### Claim 9 (depends on 8)

The method of claim 8, wherein said frangible linker is selected from the group consisting of esters, thioesters, thionoesters, dithioic acids, sulfates, sulfonates, phosphates, phosphonates, and amides.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the alkylating compound is β-alanine, N-(acridin-9-yl), 2-[bis(2-chloroethyl)amino]ethyl ester.

### Claim 11 (depends on 1)

The method according to claim 1, wherein administration is achieved through the use of a system selected from the group consisting of catheters, stents, and endoluminal paving.

### Claim 12 (depends on 11)

The method according to claim 11, wherein administration is achieved through the use of an intravascular drug delivery catheter.

### Claim 13 (depends on 12)

The method of claim 12, wherein the catheter is selected from the group consisting of an infusion sleeve catheter, a pressure-driven catheter and a double balloon catheter.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method further comprises administration of a quencher.

### Claim 15 (depends on 14)

The method of claim 14, wherein the quencher is administered locally.

### Claim 16 (depends on 14)

The method of claim 14, wherein the quencher is administered systemically.

### Claim 17 (depends on 14)

The method of claim 14, wherein the quencher is a thiol containing molecule.

### Claim 18 (depends on 17)

The method of claim 17, wherein the quencher is glutathione.

### Claim 19 (depends on 1)

The method of claim 1, wherein the vascular recanalization is achieved by angioplasty.

### Claim 20 (depends on 1)

The method of claim 1, wherein the local administration is of a non sustained release formulation.

### Claim 21 (depends on 20)

The method of claim 20, wherein the alkylating compound is delivered at a concentration of less than about 100 μM.

### Claim 22 (depends on 20)

The method of claim 20, wherein the alkylating compound is delivered at a concentration of less than about 1 μM.
